Health ❯ Healthcare

Weight Management

Obesity Obesity Treatment Medications Weight Loss Obesity Treatments Weight Loss Drugs Weight Loss Medications Weight Loss Treatments Pharmaceuticals Dietary Medications

10 ARTICLES

last mo.

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

New oral drugs and cheaper generics are driving interest while cost, injection aversion, uncertain long‑term effects and high payer bills are prompting cautious prescribing and tighter employer coverage.

5 ARTICLES

last mo.

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

5 ARTICLES

last mo.

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

4 ARTICLES

last mo.

GLP-1 Drugs Linked to Lower Migraine Drug Use in Women, Fewer Asthma Flares in Danish Data

6 ARTICLES

3mo ago

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

5 ARTICLES

3mo ago

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

8 ARTICLES

3mo ago

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

11 ARTICLES

3mo ago

Amazon Rolls Out Nationwide GLP-1 Care Program Through One Medical

4 ARTICLES

3mo ago

Anvisa Rejects Three Semaglutide and Liraglutide Drug Filings in Brazil

3 ARTICLES

3mo ago

Doctor Warns GLP‑1 Weight‑Loss Shots Can Reduce Bone Density

4 ARTICLES

4mo ago

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

5 ARTICLES

4mo ago

Kendra Wilkinson Plans GLP-1 Weight-Loss Shots to Drop a Few Pounds

8 ARTICLES

4mo ago

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

3 ARTICLES

4mo ago

Anvisa Authorizes Multidose Mounjaro Pen for Brazil

Weight Management

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

FDA Orders New Kidney Warning for Orlistat Weight‑Loss Pills

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

Veru Rally Follows Novo Nordisk Deal to Supply Wegovy for Phase 2b Trial

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

GLP-1 Drugs Linked to Lower Migraine Drug Use in Women, Fewer Asthma Flares in Danish Data

Never miss stories about

Weight Management

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

Amazon Rolls Out Nationwide GLP-1 Care Program Through One Medical

Anvisa Rejects Three Semaglutide and Liraglutide Drug Filings in Brazil

Doctor Warns GLP‑1 Weight‑Loss Shots Can Reduce Bone Density

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

Kendra Wilkinson Plans GLP-1 Weight-Loss Shots to Drop a Few Pounds

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

Anvisa Authorizes Multidose Mounjaro Pen for Brazil

Never miss stories about

Weight Management